TCRX Stock Analysis: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$0.97
0.13 (15.33%)
▲
5d:
+5.3%
30d:
-9.46%
90d:
-5.94%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $0.97, which is considered oversold relative to its 30-day fair value range of $0.92 to $1.05.
Technical Outlook: Technically, TCRX is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 15.3% recently.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+519.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TCRX is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 15.3% recently.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+519.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.92 -
$1.05
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+15.3%)
- BULLISH: Trading 519.3% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.13
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.09
Wall Street Target
$6.00
(+519.3%)
Revenue Growth (YoY)
-54.8%
Share & Embed Analysis
Last updated: June 27, 2026 8:08 AM ET
Data refreshes hourly during market hours. Next update: 9:08 AM
Data refreshes hourly during market hours. Next update: 9:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 56 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
